How does one assess early rheumatoid arthritis in daily clinical practice?

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 1, 2001, Pages 67-76

  Van Riel, Piet L C M ^a   Schumacher, H Ralph ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Assessment; Daily clinical practice; Disease activity score; Prognostic factors; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN M; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ACCURACY; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG RESPONSE; EARLY DIAGNOSIS; HUMAN; MEDICAL ASSESSMENT; PATIENT MONITORING; POLYARTHRITIS; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RATING SCALE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0035031897     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2000.0126     Document Type: Article

References (61)

1. Clinical assessment and clinical trials in rheumatoid arthritis
2. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis
3. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
4. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
5. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis
6. Safety and effectiveness of leflunomide in the treatment of patients with rheumatoid arthritis
7. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
8. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
9. The development of disability in rheumatoid arthritis
10. Factors predicting outcome of rheumatoid arthritis: Results of a followup study
11. Inflammatory polyarthritis in the community is not a benign disease: Predicting functional disability one year after presentation
12. Prognostic values of early features in rheumatoid disease
13. Factors predicting death, survival, and functional status in a prospective study of rheumatoid disease over fifteen years of disease
14. The assessment and prediction of functional disability in rheumatoid arthritis
15. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective followup study of 147 patients
16. Early rheumatoid arthritis onset, course and outcome over 2 years
17. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate and hemoglobin. Long term course and association to radiographic progression
18. Prediction of erosiveness and rates of development of new erosions in early rheumatoid arthritis
19. Genetic typing of patients with inflammatory arthritis at presentation is predictive of outcome
20. The influence of HLA-DRBI genes on disease severity in rheumatoid arthritis
21. Homozygosity for the HLA-DRBI allele selects for extra-articular manifestation in rheumatoid arthritis
22. HLA-DR4 as a predictor of outcome three years after onset of rheumatoid arthritis
23. The prognostic value of HLA-DR4 and B27 antigens in early rheumatoid arthritis
24. The prognostic value of the antiperinuclear factor, determined by a recently developed peptide-based ELISA, using anti citrulline-containing peptide antibodies (anti-CCP) in patients with recent-onset rheumatoid arthritis
25. HLA-DBRI typing in rheumatoid arthritis: Predicting response to specific treatments
26. Factors predicting outcome of rheumatoid arthritis: Results of a followup study
27. Predictors of the longterm outcome of early synovitis: A five year follow-up study
28. HLA-DR antigens, GM allotypes, and anti-allotypes in early rheumatoid arthritis - Their relation to disease progression
29. Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis
30. Anti SA antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis
31. Tissue cytokine patterns distinguish variants of rheumatoid synovitis
32. Prevalence of chlamydia trachomatis by PCR in the synovium of patients with early rheumatoid arthritis
33. Early aggressive DMARD therapy. The key to slowing disease progression in early rheumatoid arthritis
34. Clinical assessment of the 1987 ACR criteria for rheumatoid arthritis
35. Interrelationship of outcome measures and process variables in early rheumatoid arthritis
36. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study
37. Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis
38. Currently used second-line agents: Do they control the disease course?
39. Judging disease activity in clinical practice in rheumatoid arthritis. First step in the development of a 'disease activity score'
40. Modified disease activity scores that include twenty-eight-joint counts
41. Validity of single variables and indices to measure disease activity in rheumatoid arthritis
42. The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis
43. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
44. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis
45. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts
46. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials
47. ACR20: Clinical or statistical significance?
48. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?
49. Comparison of ACR response, numeric ACR, and ACR AUC as measures of clinical improvement in RA clinical trials
50. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial)
51. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis
52. Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis
53. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity
54. The rapid assessment of disease activity in rheumatology (RADAR) questionnaire
55. Self-assessment of disease activity by patients with rheumatoid arthritis
56. Validity and reproducibility of self-administered joint counts. A large prospective longitudinal followup study in patients with rheumatoid arthritis
57. A self administered rheumatoid arthritis disease activity index (RADAI) for epidemiological research: Psychometric properties and correlation with parameters of disease activity
58. Preliminary criteria for remission in rheumatoid arthritis
59. Remission in a prospective study of patients with rheumatoid arthritis. ARA preliminary remission criteria in relation to the disease activity score
60. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index
61. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis